CYP – Cynata Therapeutics Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Cynata Therapeutics Limited is an Australia-based company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for potential human therapeutic use, which the Company has branded Cymerus. The Cymerus technology represents a regenerative medicine that facilitates large-scale manufacture of uniform, potent MSCs from a single donor and a single donation, enabling the development of therapeutic stem cell products. This compares to conventional MSC technologies that require multiple donors and multiple donations. Its Cymerus technology has the potential to revolutionize the manufacture of MSC based therapeutic products for commercial use. The Company’s clinical development products candidates include graft-versus-host-disease, critical limb ischemia, osteoarthritis, acute respiratory distress syndrome, diabetic wounds, idiopathic pulmonary fibrosis and renal transplantation.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Responses